SKP, Astralis delivery deal

SkyePharma (LSE:SKP; SKYE) granted access to its DepoFoam and other delivery technologies to Astralis (Florham Park, N.J.) for a $5 million license fee. Astralis will use the technology to deliver its injectable vaccine therapy Psoraxine to treat psoriasis. SKP also will contribute services for the development of a second generation Psoraxine through Phase II trials, after which SKP has an option to acquire a global license to the compound. The companies anticipate submitting an IND for Phase Ib trials of the second generation compound in the first half of 2002. ...